EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites35
Patients885

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	486
New Zealand	173
Finland	79
Switzerland	59
Saudi Arabia	44
Ireland	31
Slovenia	12
Germany	1
Total	885